Home » Health

Health

Camp prep can make summers better for kids

(Reuters Health) – Kids may have a much better – and safer – time at summer camp when parents plan ahead to make sure programs are a good fit for their child and capable of handling any health issues that may arise, U.S. pediatricians say. By the time school’s out for summer, parents and guardians should feel confident that their ...

Read More »

Average pregnant woman in U.S. may have poor nutrition

Average pregnant woman in U.S. may have poor nutrition

(Reuters Health) – Many pregnant women in the U.S. may not be getting enough of certain crucial nutrients, while others may be getting too much, a new study suggests. FILE PHOTO: A pregnant woman stands on a scale before receiving a prenatal exam at the Maternity Outreach Mobile in Phoenix, Arizona October 8, 2009. REUTERS/Joshua Lott Based a study of ...

Read More »

FDA approves drug for loss of sexual desire in women

FDA approves drug for loss of sexual desire in women

(Reuters) – The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals’ drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as “female Viagra”. FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. Picture taken ...

Read More »

Merck CEO sees legal challenge if U.S. adopts drug pricing based on other countries

NEW YORK (Reuters) – Merck & Co Chief Executive Ken Frazier said on Thursday a rule to base the price the U.S. government pays for some prescription drugs in it Medicare program on lower prices in other countries would face legal challenges if adopted. FILE PHOTO: Ken Frazier, Chairman and CEO, Merck & Co., speaks during a meeting of the ...

Read More »

U.S. group says Novartis MS drug price out of line with benefit

FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Jan. 25, 2017. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple sclerosis drug Mayzent, calling its $88,561 list price “far out of line” compared with its benefits for patients. The ...

Read More »